Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Frank Morich purchased 15,000 shares of the stock in a transaction dated Thursday, November 12th. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $15,000.00. Following the transaction, the director owned 15,000 shares of the company's stock, valued at approximately $15,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Perspective Therapeutics Price Performance
Shares of CATX stock opened at $0.94 on Monday. The firm's 50 day moving average is $2.11 and its 200 day moving average is $3.44. Perspective Therapeutics, Inc. has a 12 month low of $0.78 and a 12 month high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, research analysts expect that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently issued reports on CATX shares. Royal Bank Of Canada lowered Perspective Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price objective for the company from $14.00 to $4.00 in a research note on Monday, October 26th. BTIG Research restated a "buy" rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. BMO Capital Markets reaffirmed an "outperform" rating on shares of Perspective Therapeutics in a report on Friday, October 30th. William Blair started coverage on Perspective Therapeutics in a research report on Friday, September 18th. They set an "outperform" rating on the stock. Finally, Bank of America lowered their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $10.10.
View Our Latest Analysis on Perspective Therapeutics
Institutional Investors Weigh In On Perspective Therapeutics
Large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in Perspective Therapeutics by 391.6% during the first quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company's stock worth $1,877,000 after buying an additional 358,540 shares in the last quarter. Avidity Partners Management LP raised its holdings in shares of Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock valued at $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of Perspective Therapeutics in the 1st quarter valued at about $1,581,000. Yu Fan bought a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $4,401,000. Finally, Commodore Capital LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $26,424,000. Institutional investors own 54.66% of the company's stock.
About Perspective Therapeutics
(
Get Free Report)
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.